NO20011351L - Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav - Google Patents

Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav

Info

Publication number
NO20011351L
NO20011351L NO20011351A NO20011351A NO20011351L NO 20011351 L NO20011351 L NO 20011351L NO 20011351 A NO20011351 A NO 20011351A NO 20011351 A NO20011351 A NO 20011351A NO 20011351 L NO20011351 L NO 20011351L
Authority
NO
Norway
Prior art keywords
inhibitor
combination
treating diabetes
diabetes
glyburide
Prior art date
Application number
NO20011351A
Other languages
English (en)
Other versions
NO20011351D0 (no
Inventor
Jeffrey A Robl
Rex A Parker
Scott A Biller
Haris Jamil
Bruce L Jacobson
Krishna Kodukula
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011351(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20011351D0 publication Critical patent/NO20011351D0/no
Publication of NO20011351L publication Critical patent/NO20011351L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steroid Compounds (AREA)

Abstract

Det beskrives en fremgangsmåte for behandling av diabetes og beslektede sykdommer, spesielt type 2-diabetes, som benytter en aP2-inhibitor eller en kombinasjon av en aP2-inhibitor og et annet antidiabetisk middel, så som metformin, glyburide, troglitazone og/eller insulin.
NO20011351A 1998-09-17 2001-03-16 Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav NO20011351L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10067798P 1998-09-17 1998-09-17
PCT/US1999/020946 WO2000015229A1 (en) 1998-09-17 1999-09-13 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (2)

Publication Number Publication Date
NO20011351D0 NO20011351D0 (no) 2001-03-16
NO20011351L true NO20011351L (no) 2001-05-11

Family

ID=22280975

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20011351A NO20011351L (no) 1998-09-17 2001-03-16 Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav
NO20011352A NO20011352L (no) 1998-09-17 2001-03-16 Fremgangsmåte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20011352A NO20011352L (no) 1998-09-17 2001-03-16 Fremgangsmåte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav

Country Status (30)

Country Link
US (1) US20020035064A1 (no)
EP (2) EP1121129B1 (no)
JP (2) JP2002524517A (no)
KR (2) KR20010075150A (no)
CN (2) CN1319012A (no)
AT (1) ATE406898T1 (no)
AU (2) AU755563B2 (no)
BG (2) BG105431A (no)
BR (2) BR9913831A (no)
CA (2) CA2344300A1 (no)
CO (2) CO5130026A1 (no)
CZ (2) CZ2001965A3 (no)
DE (1) DE69939481D1 (no)
EE (2) EE200100155A (no)
ES (1) ES2311306T3 (no)
GE (2) GEP20033045B (no)
HU (2) HUP0104108A2 (no)
ID (2) ID28450A (no)
IL (2) IL141786A0 (no)
LT (2) LT4870B (no)
LV (2) LV12686B (no)
NO (2) NO20011351L (no)
NZ (2) NZ510209A (no)
PE (2) PE20001056A1 (no)
PL (2) PL346660A1 (no)
SK (1) SK3202001A3 (no)
TR (2) TR200100773T2 (no)
UY (2) UY25714A1 (no)
WO (2) WO2000015230A1 (no)
ZA (2) ZA200207430B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834508T2 (de) * 1997-11-19 2006-11-23 Takeda Pharmaceutical Co. Ltd. Apoptoseinhibitoren
EP1151092B1 (en) * 1999-02-12 2008-12-31 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions with afabp antisens nucleic acids
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU3294701A (en) 2000-01-28 2001-08-07 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
US6670380B2 (en) 2000-11-20 2003-12-30 Bristol-Myers Squibb Co. Pyridone inhibitors of fatty acid binding protein and method
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
EP1414461A4 (en) 2001-07-13 2005-10-26 Bristol Myers Squibb Co PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD
US20030144350A1 (en) * 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
ATE490244T1 (de) 2003-01-27 2010-12-15 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
EP1620089A4 (en) * 2003-03-26 2008-12-24 Crc For Asthma Ltd Therapeutic and prophylactic compositions and their uses
WO2004096977A2 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
ES2399721T5 (es) 2004-03-05 2016-05-25 Univ Pennsylvania Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
ES2306165T3 (es) 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
AU2006214164B2 (en) 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
CN101300232A (zh) 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
US20070088089A1 (en) * 2005-10-18 2007-04-19 Wisler Gerald L Methods for treating disorders associated with hyperlipidemia in a mammal
CA2654183A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
WO2008079398A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
AU2009314299A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
JP5984396B2 (ja) * 2009-03-05 2016-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 分泌されたａＰ２およびこれを阻害する方法
JP6514282B2 (ja) * 2014-03-24 2019-05-15 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6223376B2 (ja) * 2014-03-24 2017-11-01 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP2018515082A (ja) 2015-04-30 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 代謝障害を処置するための抗ａｐ２抗体及び抗原結合剤
CA3026521A1 (en) * 2016-06-27 2018-01-04 President And Fellows Of Harvard College Compounds useful to treat metabolic disorders
WO2018227200A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
FR2156486A1 (en) 1971-10-22 1973-06-01 Roussel Uclaf Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (no) 1974-06-07 1981-03-18
GB1507032A (en) 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
GR1000959B (el) 1987-05-22 1993-03-16 Squibb & Sons Inc ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΡΕΔΟΥΚΤΑΣΗΣ HMG-CοA ΠΟΥ ΠΕΡΙΕΧΕΙ ΦΩΣΦΟΡΟ,ΝΕΑ ΕΝΔΙΑΜΕΣΑ ΚΑΙ ΜΕΘΟΔΟΣ
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr) 1990-06-14 1994-05-06 Bellon Laboratoires Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de) 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
JPH09506894A (ja) * 1993-12-20 1997-07-08 藤沢薬品工業株式会社 ４，５−ジアリールオキサゾール誘導体
US5599770A (en) 1994-07-15 1997-02-04 Kureha Kagaku Kogyo Kabushiki Kaisha Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en) 1996-01-05 1996-03-06 Foster Wheeler Petrol Dev Ltd Spacing bouy for flexible risers
AUPO134596A0 (en) 1996-08-01 1996-08-22 Jal Pastoral Co. Pty Ltd Demountable article carrier for motor vehicles
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
BG105431A (en) 2001-12-29
JP2002524518A (ja) 2002-08-06
CN1319012A (zh) 2001-10-24
BG105432A (en) 2001-12-29
NO20011351D0 (no) 2001-03-16
JP2002524517A (ja) 2002-08-06
UY25713A1 (es) 2001-08-27
NZ510209A (en) 2003-07-25
CO5130025A1 (es) 2002-02-27
CO5130026A1 (es) 2002-02-27
ZA200207433B (en) 2003-10-27
LT4871B (lt) 2001-12-27
LV12686B (lv) 2001-10-20
WO2000015230A1 (en) 2000-03-23
LT2001023A (en) 2001-08-27
AU6143799A (en) 2000-04-03
CZ2001964A3 (cs) 2002-01-16
LT4870B (lt) 2001-12-27
HUP0104108A2 (hu) 2002-03-28
UY25714A1 (es) 2001-08-27
CA2344309A1 (en) 2000-03-23
EE04356B1 (et) 2004-10-15
PE20001056A1 (es) 2000-12-24
NZ510207A (en) 2003-08-29
CZ2001965A3 (cs) 2002-02-13
TR200100774T2 (tr) 2001-12-21
GEP20033044B (en) 2003-08-25
EE200100155A (et) 2002-08-15
CN1317970A (zh) 2001-10-17
EP1113801A1 (en) 2001-07-11
PE20001047A1 (es) 2000-12-24
EP1121129B1 (en) 2008-09-03
ZA200207430B (en) 2003-09-16
AU754488B2 (en) 2002-11-14
IL141785A0 (en) 2002-03-10
DE69939481D1 (de) 2008-10-16
PL346660A1 (en) 2002-02-25
AU6387799A (en) 2000-04-03
ES2311306T3 (es) 2009-02-01
AU755563B2 (en) 2002-12-12
ID27833A (id) 2001-04-26
GEP20033045B (en) 2003-08-25
LT2001022A (en) 2001-08-27
ID28450A (id) 2001-05-24
NO20011352L (no) 2001-05-11
WO2000015229A1 (en) 2000-03-23
LV12687A (en) 2001-07-20
KR20010075150A (ko) 2001-08-09
BR9913833A (pt) 2001-05-29
ATE406898T1 (de) 2008-09-15
US20020035064A1 (en) 2002-03-21
LV12686A (en) 2001-07-20
NO20011352D0 (no) 2001-03-16
SK3202001A3 (en) 2002-04-04
HUP0104240A2 (hu) 2002-03-28
TR200100773T2 (tr) 2001-07-23
BR9913831A (pt) 2001-05-29
EE200100154A (et) 2002-12-16
EP1121129A4 (en) 2002-10-16
KR20010079842A (ko) 2001-08-22
EP1121129A1 (en) 2001-08-08
LV12687B (lv) 2001-10-20
PL346661A1 (en) 2002-02-25
CA2344300A1 (en) 2000-03-23
IL141786A0 (en) 2002-03-10
EP1113801A4 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
NO20011351L (no) Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav
LT2001092A (en) HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND USE THEREOF
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
NO305074B1 (no) Aminosyrederivater, medikamenter inneholdende disse forbindelser og anvendelser derav
ATE238802T1 (de) Zusammensetzung von glibenclamid und metformine zur behandlung von diabetes mellitis typ ii
DK0749421T3 (da) Sulfonamidderivater som aspartylproteaseinhibitorer
EP0400557A3 (en) Developing apparatus and process cartridge with same
NO20005161L (no) N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
FI972628A0 (fi) Uudet sulfonamidit
DK1214936T3 (da) Anvendelse af thiazolidin- eller pyrrolidinderivater af aminosyrer som antihyperglykæmiske midler
PT89502A (pt) Processo para a preparacao de derivados de 2-(2-hidroxi-3-fenoxi-metilo e de composicoes farmaceuticas que os contem
NO951790L (no) Nytt arylpropionsyrederivat, fremgangsmåte ved dets fremstilling og dets anvendelse som et analgetisk middel
NO306930B1 (no) Anvendelse av 2-amino-6-n-propylamino-4,5,6,7- tetrahydrobenzotiazol (Pramipexol) som et antidepressivt middel
PT902022E (pt) Novos derivados de benzofuranona e processo para a sua producao
ID16266A (id) Perlakuan dan pencegahan pankreatitis
EE03392B1 (et) Aminoguanidiinkarboksülaadid insuliinisõltumatu suhkurtõve raviks
ES2187534T3 (es) Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida.
AU6454196A (en) Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
BR9807785A (pt) Processo para a preparação do composto, e, composto
ECSP993146A (es) Metodo de tratameinto para la diabetes empleando un inhibidor ap2 y su combinacion
DE69925301D1 (de) Zusammensetzung von riluzol und alpha-tocopherol
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia